Polyunsaturated fatty acids (PUFAs) for attention deficit hyperactivity disorder in children and adolescents

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Sinn, John K H ^a   Gillies, Donna ^b   Ross, Melinda J ^c   Lad, Sagar S ^c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b Central Sydney Area Mental Health Service   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; METHYLPHENIDATE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID;

ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CELL HETEROGENEITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INFORMATION PROCESSING; MEDICAL RESEARCH; MORBIDITY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADOLESCENT; CHILD; CHILD BEHAVIOR CHECKLIST; CONTROLLED STUDY; COST OF ILLNESS; DECREASED APPETITE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENVIRONMENTAL FACTOR; HEADACHE; HEREDITY; INSOMNIA; IRRITABILITY; OUTCOME ASSESSMENT; PSYCHOTHERAPY; SIDE EFFECT; STATE TRAIT ANXIETY INVENTORY; STOMACH PAIN; SUICIDAL BEHAVIOR; SUPPLEMENTATION; WEIGHT REDUCTION;

EID: 70049102350     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007986     Document Type: Review

References (60)

1. Achenbach TM, Edelbrock CS. Manual for the Child Behavior Check-list. Burlington, VT: University of Vermont, Department of Psychiatry, 1983.
2. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
3. Aman MG, Mitchell EA, Turbott SH. The effects of essential fatty acid supplementation by Efamol in hyperactive children. Journal of Abnormal Child Psychology 1987;15(1):75-90. (Pubitemid 17039438)
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th Edition. Washington DC: APA, 1994.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (text revision). Washington, DC: APA, 2000.
6. Banaschewski T, Roessner V, Dittmann RW Santosh PJ, Rothenberger A. Non-stimulant medications in the treatment of ADHD. European Child & Adolescent Psychiatry 2004;13(Suppl 1):102-116
7. Barkley RA. Diagnosis and assessment of attention deficit-hyperactivity disorder. Comprehensive Mental Health Care 1991;1(1):27-43.
8. Barkley R. Attention-deficit hyperactivity disorders: a handbook for diagnosis and treatment. 2nd Edition. New York: Guilford Press, 1998.
9. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biological Psychiatry 2005;57(11):1215-1220
10. Brue AW, Oakland TD. Alternative treatments for attention-deficit/ hyperactivity disorder: does evidence support their use?. Alternative Therapies in Health Medicine 2002;8(1):68-70, 72-74
11. Burgess JR, Stevens L, Zhang W, Peck L. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. American Journal of Clinical Nutrition 2000;71(Suppl 1):327-330. (Pubitemid 30046136)
12. Cantwell DP. Attention deficit disorder: a review of the past 10 yearssee comment. Journal of the American Academy of Child Adolescent Psychiatry 1996;35(8):978-987 (Pubitemid 26266328)
13. Chen J-R, Hsu S-F, Hsu C-D, Hwang L-H, Yang S-C. Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. The Journal of Nutritional Biochemistry 2004 Aug;15(8):467-472
14. Daley KC. Update on attention-deficit/hyperactivity disorder. Current Opinion in Pediatrics 2004;16(2):217-226
15. Faraone SV. Genetics of childhood disorders: XX ADHD Part 4: is ADHD genetically heterogeneous?. Journal of the American Academy of Child Adolescent Psychiatry 2000;39(11):1455-1457 (Pubitemid 30800727)
16. Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders?. Journal of Clinical Psychiatry 2003;64(Suppl 11):9-13. (Pubitemid 37169643)
17. Findling RL, Dogin JW. Psychopharmacology of ADHD in children and adolescents. Journal of Clinical Psychiatry 1998;59(7):42-49
18. Furman L. What is attention-deficit hyperactivity disorder (ADHD)?. Journal of Child Neurology 2005;20(12):994-1002. (Pubitemid 43299333)
19. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Molecular Psychiatry 1997;2(4):311-313. (Pubitemid 27450313)
20. Goodman R, Stevenson J. A twin study of hyperactivity II: the aetiological role of genes, family relationships and perinatal adversity. Journal of Child Psychology and Psychiatry 1989;30(5):691-709. (Pubitemid 19230569)
21. Goodman, R. The Strengths and Difficulties Questionnaire: A Research Note. Journal of Child Psychology and Psychiatry 1997;38(5):581-586. (Pubitemid 27341892)
22. Haag M. Essential fatty acids and the brain. Canadian Journal of Psychiatry 2003;48(3):3195-3203
23. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry 2006;63(3):332-339. (Pubitemid 43345358)
24. Harpin VA. The effect of ADHD on the life of an individual their family and community from preschool to adult life. Archives of Disease in Childhood 2005;90(Suppl 1):i2-7.
25. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.
26. Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/ hyperactivity disorder - a placebo-controlled double-blind study. European Journal Of Clinical Nutrition 2004;58(3):467-473. (Pubitemid 38443707)
27. Innis SM. The role of dietary n-6 and n-3 fatty acids in the developing brain. Developmental Neuroscience 2000;22(5-6):474-480.
28. Klassen A, Miller A, Raina P, Lee SK, Olsen L. Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 1999;44(10):1007-1016 (Pubitemid 30062400)
29. Kovacs M. Children's Depression Inventory. https://www.mhs.com/ecom/ (3jkh5055rnqsekfhnxgzn145)/TechBrochures/CDI.pdf 1992 [accessed 18 May 2007].
30. Krause KH, Dresel SH, Krause J, la Fougere C, Ackenheil M. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neuroscience Biobehavioral Reviews 2003;27(7):605-613 (Pubitemid 37414909)
31. Li D, Sham PC, Owen MJ, He L. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Human Molecular Genetics 2006;15(14):2276-2284 (Pubitemid 43994869)
32. Linnet KM, Dalsgaard S, Obel C, Wisborg K, Henriksen TB, Rodriguez A, Kotimaa A, Moilanen I, Thomsen PH, Olsen J, Jarvelin MR. Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. American Journal of Psychiatry 2003;160(6):1028-1040 (Pubitemid 41070961)
33. Mitchell EA, Aman MG, Turbott SH, Manku M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clinical Pediatrics 1987;26(8):406-411 (Pubitemid 18089640)
34. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-613 (Pubitemid 28380142)
35. Morrell J, Murray L. Parenting and the development of conduct disorder and hyperactive symptoms in childhood: a prospective longitudinal study from 2 months to 8 years. Journal of Child Psychology and Psychiatry 2003;44(4):489-508. (Pubitemid 36943982)
36. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). Journal of the American Academy of Child & Adolescent Psychiatry 2000;39(2):182-193
37. Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. Journal of Pediatric Psychology 2007;32(6):711-727 (Pubitemid 47356048)
38. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. American Journal of Psychiatry 2007;164(6):942-948 (Pubitemid 46972911)
39. Raskin LA, Shaywitz SE, Shaywitz BA, Anderson GM, Cohen DJ. Neurochemical correlates of attention deficit disorder. Pediatric Clinics of North America 1981;31(2):387-396
40. Richardson AJ, Puri BK. The potential role of fatty acids in attention-deficit/hyperactivity disorder. Prostaglandin, Leukotrienes and Essential Fatty Acids 2000;63(1-2):79-87.
41. Richardson AJ, Puri BK. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2002;26(2):233-239.
42. Richardson AJ. Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukotrienes and Essential Fatty Acids 2004;70(4):383-390.
43. Schab DW, Trinh NH. Do artificial food colors promote hyperactivity in children with hyperactive syndromes? A meta-analysis of double-blind placebo-controlled trials. Journal of Developmental Behavioral Pediatrics 2004;25(6):423-434
44. Shaywitz B, Fletcher J, Shaywitz S. Attention-deficit/hyperactivity disorder. Advances in Pediatrics 1997;44:331-367
45. Simeon JG, Wiggins DM. Pharmacotherapy of attention deficit hyperactivity disorder. Canadian Journal of Psychiatry 1993;38:443-448 (Pubitemid 23306861)
46. Simmer K, Schulzke SM, Patole S. Longchain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database of Systematic Reviews 2008, Issue 1.[Art. No.: CD000375. DOI: 10.1002/14651858.CD000375.pub3] (Pubitemid 351807607)
47. Simmer K, Patole S, Rao S. Longchain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database of Systematic Reviews 2008, Issue 1.[Art. No.: CD000376. DOI: 10.1002/14651858.CD000376.pub2] (Pubitemid 351807607)
48. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. American Journal of Clinical Nutrition 1991;54(3):438-463.
49. Spielberger CD. Manual for the State-Trait Anxiety Inventory for Children. Palo Alto, CA: Consulting Psychologists Press, 1973.
50. Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, Lipp SR, Burgess JR. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. American Journal of Clinical Nutrition 1995;62(4):761-768.
51. Stevens L, Zhang W, Peck L, Kuczek T, Grevstad N, Mahon A, Zentall SS, Arnold LE, Burgess JR. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003;38(10):1007-1021. (Pubitemid 37444624)
52. Swanson JM, McBumett, Wigal T. Effect of stimulant medication on children with attention deficit disorder: a "review of reviews". Exceptional Children 1993;60(2):154-162
53. Swanson J. Attention deficit/hyperactivity disorder children with a 7-repeat allele of the dopamine receptor D4 gene have extreme behaviour but normal performance on critical neuropsychology tests of attention.. Proceedings of the National Academy of Sciences 2000;97:4754-4759 (Pubitemid 30238630)
54. Swanson JM, Kinsbourne M, Nigg J, Lanphear B, Stefanatos GA, Volkow N, Taylor E, Casey BJ, Castellanos FX, Wadhwa PD. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychology Review 2007;17(1):39-59. (Pubitemid 46355008)
55. Varni JW, Seid M, Kurtin PS. PedsQL™ 4.0: Reliability and Validity of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales in Healthy and Patient Populations. Medical Care 2001;39(8):800-812 (Pubitemid 33686263)
56. Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics 2001;139(2):189-196.
57. Wainwright PE. Do essential fatty acids play a role in brain and behavioral development?. Neuroscience And Biobehavioral Reviews 1992;16(2):193-205.
58. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: WHO, 1992.
59. Wilens TE. Attention-deficit/hyperactivity disorder and the substance use disorders: The nature of the relationship who is at risk and treatment issues. Primary Psychiatry 2004;11(7):63-70. (Pubitemid 39006710)
60. Zappitelli M, Pinto T, Grizenko N. Pre- peri- and postnatal trauma in subjects with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 2001;46(6):542-548 (Pubitemid 32861421)